Cargando…

Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review

The opioid epidemic has been an ongoing public health concern in the United States (US) for the last few decades. The number of overdose deaths involving opioids, hereafter referred to as overdose deaths, has increased yearly since the mid-1990s. One treatment modality for opioid use disorder (OUD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Risby, Joanna, Schlesinger, Erica, Geminn, Wesley, Cernasev, Alina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514867/
https://www.ncbi.nlm.nih.gov/pubmed/37736904
http://dx.doi.org/10.3390/pharmacy11050131
_version_ 1785108819850821632
author Risby, Joanna
Schlesinger, Erica
Geminn, Wesley
Cernasev, Alina
author_facet Risby, Joanna
Schlesinger, Erica
Geminn, Wesley
Cernasev, Alina
author_sort Risby, Joanna
collection PubMed
description The opioid epidemic has been an ongoing public health concern in the United States (US) for the last few decades. The number of overdose deaths involving opioids, hereafter referred to as overdose deaths, has increased yearly since the mid-1990s. One treatment modality for opioid use disorder (OUD) is medication-assisted treatment (MAT). As of 2022, only three pharmacotherapy options have been approved by the Food and Drug Administration (FDA) for treating OUD: buprenorphine, methadone, and naltrexone. Unlike buprenorphine and naltrexone, methadone dispensing and administrating are restricted to opioid treatment programs (OTPs). To date, Tennessee has no medication units, and administration and dispensing of methadone is limited to licensed OTPs. This review details the research process used to develop a policy draft for medication units in Tennessee. This review is comprised of three parts: (1) a rapid review aimed at identifying obstacles and facilitators to OTP access in the US, (2) a descriptive analysis of Tennessee’s geographic availability of OTPs, pharmacies, and federally qualified health centers (FQHCs), and (3) policy mapping of 21 US states’ OTP regulations. In the rapid review, a total of 486 articles were imported into EndNote from PubMed and Embase. After removing 152 duplicates, 357 articles were screened based on their title and abstract. Thus, 34 articles underwent a full-text review to identify articles that addressed the accessibility of methadone treatment for OUD. A total of 18 articles were identified and analyzed. A descriptive analysis of Tennessee’s availability of OTP showed that the state has 22 OTPs. All 22 OTPs were matched to a county and a region based on their address resulting in 15 counties (16%) and all three regions having at least one OTP. A total of 260 FQHCs and 2294 pharmacies are in Tennessee. Each facility was matched to a county based on its address resulting in 70 counties (74%) having at least one FQHC and 94 counties (99%) having at least one pharmacy. As of 31 December 2022, 17 states mentioned medication units in their state-level OTP regulations. Utilizing the regulations for the eleven states with medication units and federal guidelines, a policy draft was created for Tennessee’s medication units.
format Online
Article
Text
id pubmed-10514867
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105148672023-09-23 Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review Risby, Joanna Schlesinger, Erica Geminn, Wesley Cernasev, Alina Pharmacy (Basel) Review The opioid epidemic has been an ongoing public health concern in the United States (US) for the last few decades. The number of overdose deaths involving opioids, hereafter referred to as overdose deaths, has increased yearly since the mid-1990s. One treatment modality for opioid use disorder (OUD) is medication-assisted treatment (MAT). As of 2022, only three pharmacotherapy options have been approved by the Food and Drug Administration (FDA) for treating OUD: buprenorphine, methadone, and naltrexone. Unlike buprenorphine and naltrexone, methadone dispensing and administrating are restricted to opioid treatment programs (OTPs). To date, Tennessee has no medication units, and administration and dispensing of methadone is limited to licensed OTPs. This review details the research process used to develop a policy draft for medication units in Tennessee. This review is comprised of three parts: (1) a rapid review aimed at identifying obstacles and facilitators to OTP access in the US, (2) a descriptive analysis of Tennessee’s geographic availability of OTPs, pharmacies, and federally qualified health centers (FQHCs), and (3) policy mapping of 21 US states’ OTP regulations. In the rapid review, a total of 486 articles were imported into EndNote from PubMed and Embase. After removing 152 duplicates, 357 articles were screened based on their title and abstract. Thus, 34 articles underwent a full-text review to identify articles that addressed the accessibility of methadone treatment for OUD. A total of 18 articles were identified and analyzed. A descriptive analysis of Tennessee’s availability of OTP showed that the state has 22 OTPs. All 22 OTPs were matched to a county and a region based on their address resulting in 15 counties (16%) and all three regions having at least one OTP. A total of 260 FQHCs and 2294 pharmacies are in Tennessee. Each facility was matched to a county based on its address resulting in 70 counties (74%) having at least one FQHC and 94 counties (99%) having at least one pharmacy. As of 31 December 2022, 17 states mentioned medication units in their state-level OTP regulations. Utilizing the regulations for the eleven states with medication units and federal guidelines, a policy draft was created for Tennessee’s medication units. MDPI 2023-08-22 /pmc/articles/PMC10514867/ /pubmed/37736904 http://dx.doi.org/10.3390/pharmacy11050131 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Risby, Joanna
Schlesinger, Erica
Geminn, Wesley
Cernasev, Alina
Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review
title Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review
title_full Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review
title_fullStr Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review
title_full_unstemmed Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review
title_short Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review
title_sort methadone treatment gap in tennessee and how medication units could bridge the gap: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514867/
https://www.ncbi.nlm.nih.gov/pubmed/37736904
http://dx.doi.org/10.3390/pharmacy11050131
work_keys_str_mv AT risbyjoanna methadonetreatmentgapintennesseeandhowmedicationunitscouldbridgethegapareview
AT schlesingererica methadonetreatmentgapintennesseeandhowmedicationunitscouldbridgethegapareview
AT geminnwesley methadonetreatmentgapintennesseeandhowmedicationunitscouldbridgethegapareview
AT cernasevalina methadonetreatmentgapintennesseeandhowmedicationunitscouldbridgethegapareview